Hindustan Times (Amritsar)

Don’t create a world of immunity haves and have-nots

- Binayak Dasgupta binayak.dasgupta@htlive.com The views expressed are personal

On November 23, Qantas CEO Alan Joyce said his airline is considerin­g a rule requiring passengers to get a coronaviru­s vaccine before they can board its planes. Joyce added the idea was being discussed in a broader conversati­on among his peers, although the Internatio­nal Air Transport Associatio­n, the industry’s lobby group, called the idea “a bit premature”. Premature as it may be, similar ideas — such as what has been referred to as immunity passport — have been spoken of in the context of the pandemic, and as vaccines begin shipping, it is likely to take centre-stage soon.

There are legal and practical precedents for what Joyce suggested, known as vaccinatio­n certificat­es recognised by the World Health Organizati­on’s Internatio­nal Health Regulation­s (IHR). At present, the sole universal disease recognised is the Yellow Fever — passengers arriving from affected regions (mostly African and South America nations) or travelling to them may be required to produce them. Covid-19 vaccinatio­n certificat­es could be included in revised WHO recommenda­tions under its “public health emergency of internatio­nal concern” guidelines or any of 196 member-states could ask for an inclusion of it under IHR.

But mandating these certificat­es at any level, internatio­nal or domestic, comes with ethical and economic implicatio­ns till vaccines become affordable, accessible and are in adequate supply for all. Assessment­s of vaccine supply deals suggest high-income countries have secured the bulk of the supply available till the end of the next year — some have enough commitment­s to cover their population­s twice over. Once they do receive a vaccine, low and middle-income countries (LMICs) are likely to take longer to inoculate their large population­s.

The lack of adequate supply chain infrastruc­ture and electricit­y can compound these challenges, as can typically endemic issues of corruption and domestic inequity that often afflict the Global South. WHO’s State of Inequality report in 2019 found that full childhood immunisati­on — possibly the closest example of vaccines that are a must

— coverage varies wildly in LMICs. In the 67 LMICs surveyed (excluding India and China), the median coverage varied from 51% to 83% for children under the age of one. In 16 countries, less than one in four children got full immunisati­on. In 11 of these countries, children in the richest quintile were twice as likely to be immunised as children in the poorest.

Pharmaceut­ical powerhouse­s such as India and China are likely to be able to minimise their disadvanta­ge, but — at least in the case of India — estimates by experts suggest only about 30-40% of the country is likely to be vaccinated till the end of 2021. For population­s that do not have widespread coverage, this could translate into lopsided restrictio­ns on even essential travel. The difference between the immunity haves and have-nots will not just impact lives but also livelihood­s. Covid-19 has exacerbate­d inequities. People who have had the most capital have had access to better health care at a time when most public utilities have been overwhelme­d. People in white collar jobs have been able to quarantine, isolate and earn while working from home, while others have lost pay and employment as their workplaces shut.

Government­s and businesses must chart a path out of this pandemic that minimises inequities. These conversati­ons have begun in some of the richest countries, such as the United States where President Donald Trump had access to potentiall­y life-saving coronaviru­s treatment that is out of reach for ordinary Americans. It is a conversati­on that has been reignited by the high prices of the most effective vaccine candidates, which cost up to 10 times as much as the cheapest. Bioethicis­ts and philanthro­pists had indeed flagged the issue as poorer countries struggled with lack of political or economic leverage. India must evaluate any decision that could lead us to prioritise those with immunocapi­tal because the ones without it will likely be the victims of choices they did not make.

 ??  ??

Newspapers in English

Newspapers from India